Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 12,094 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $82.40, for a total value of $996,545.60. Following the completion of the transaction, the chief executive officer now directly owns 210,976 shares in the company, valued at approximately $17,384,422.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ RGEN traded down $0.69 during midday trading on Wednesday, reaching $79.88. 1,073,938 shares of the company’s stock traded hands, compared to its average volume of 461,140. The company has a quick ratio of 1.88, a current ratio of 2.25 and a debt-to-equity ratio of 0.02. The stock’s 50 day simple moving average is $91.47 and its 200-day simple moving average is $74.32. Repligen Co. has a one year low of $48.26 and a one year high of $99.25. The company has a market cap of $4.18 billion, a price-to-earnings ratio of 109.42, a P/E/G ratio of 4.82 and a beta of 1.16.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The company had revenue of $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. Repligen had a net margin of 11.42% and a return on equity of 6.92%. Repligen’s revenue for the quarter was up 48.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.14 earnings per share. Equities analysts predict that Repligen Co. will post 0.97 EPS for the current fiscal year.

Several research analysts have commented on RGEN shares. Stephens restated an “overweight” rating and set a $110.00 price objective on shares of Repligen in a report on Thursday, August 22nd. Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Repligen in a research report on Monday, August 12th. Finally, Craig Hallum raised their price target on Repligen from $80.00 to $108.00 and gave the company a “buy” rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Repligen currently has an average rating of “Buy” and a consensus price target of $101.17.

A number of hedge funds and other institutional investors have recently made changes to their positions in RGEN. Royce & Associates LP lifted its stake in shares of Repligen by 40.6% during the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 145 shares during the last quarter. Falcon Point Capital LLC boosted its holdings in shares of Repligen by 2.5% in the 1st quarter. Falcon Point Capital LLC now owns 6,922 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 167 shares in the last quarter. Summit Creek Advisors LLC boosted its holdings in shares of Repligen by 0.3% in the 2nd quarter. Summit Creek Advisors LLC now owns 84,537 shares of the biotechnology company’s stock valued at $7,266,000 after buying an additional 230 shares in the last quarter. Pitcairn Co. grew its position in shares of Repligen by 7.0% in the 2nd quarter. Pitcairn Co. now owns 3,769 shares of the biotechnology company’s stock worth $324,000 after buying an additional 245 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in shares of Repligen by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 15,117 shares of the biotechnology company’s stock worth $893,000 after buying an additional 273 shares during the last quarter. 88.66% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.